Sterling Pharma Solutions Acquires ADC Biotechnology

GHO Capital and Partners Group Invest in Sterling Pharma Solutions

May 25, 2023

Pharmaceuticals

GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.

GHO Capital Acquires Majority Stake in Sterling Pharma Solutions

February 28, 2019

Pharmaceuticals

GHO Capital has acquired a majority stake in Sterling Pharma Solutions alongside management. The investment will support Sterling's international expansion and accelerate growth of its specialist API development and GMP manufacturing capabilities from its UK base in Newcastle upon Tyne.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

Sterling Pharma Solutions Acquires Alcami's Germantown (WI) API Facility

October 1, 2020

Pharmaceuticals

Sterling Pharma Solutions, a portfolio company of GHO Capital Partners, has acquired Alcami’s Germantown, Wisconsin API development and manufacturing facility. The facility expands Sterling’s US footprint and adds cGMP capacity for complex and hazardous API projects, including plant-scale hydrogenation and cryogenic reactions.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

May 17, 2022

Healthcare Services

Alliance Pharma, an Ampersand-backed US bioanalytical CRO, acquired Drug Development Solutions (DDS), LGC’s UK-based bioanalytical and materials science testing business. Ampersand Capital Partners and KKR will be equal shareholders in the combined business to expand geographic reach, broaden laboratory capabilities, and extend the service portfolio internationally.